The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).La presente divulgación se refiere a composiciones farmacóuticas que comprenden inhibidor(es) de la histona metiltransferasa EZH2 humana, y a métodos de terapia contra el cáncer que usan el/los inhibidor(es) de EZH2.